Wed | Oct 20, 2021

Vaccine first puts spotlight on German pharma company BioNTech

Published:Friday | December 4, 2020 | 12:12 AM
In this Tuesday, November 10, 2020 file photo, windows are illuminated at the headquarters of the German biotechnology company BioNTech in Mainz, Germany.
AP In this Tuesday, November 10, 2020 file photo, windows are illuminated at the headquarters of the German biotechnology company BioNTech in Mainz, Germany.

The email that arrived in the ancient German city of Mainz shortly before 1 a.m. marked a turning point in the global effort to deliver a reliable vaccine against the coronavirus pandemic – and for the little-known biotechnology company that helped develop it.

BioNTech has at times been portrayed as the junior partner in American pharmaceutical giant Pfizer’s race to get approval for the COVID vaccine a pandemic-weary world is desperately waiting for. In fact, the company’s use of gene technology to beat the virus was key to the rapid development of the vaccine that British regulators have given the okay for emergency use early Wednesday.

Founded 12 years ago, BioNTech specialises in harnessing so-called messenger RNA, or mRNA, to train the immune system to attack hostile invaders, from viruses to tumours. Until now, the technology had never been approved for a drug in humans, but the company’s founders said they immediately saw the potential when the virus first emerged early this year.

“When we understood that this outbreak in China could become a global pandemic, we felt the obligation to start vaccine development,” BioNTech’s Chief Executive Ugur Sahin told The Associated Press in a recent interview.

“We have technologies in place which allow us to make vaccines and evaluate candidates in an ultra-fast fashion,” he said.

But Sahin, who came to Germany from Turkey with his parents as a young child, said he and his colleagues also understood that they didn’t have the means to roll out mass trials of vaccine candidates with tens of thousands of participants, a key part of testing whether the shot would be both effective and safe.

“It was very clear from the beginning that we need to go into a collaboration,” said Sahin.

He immediately reached out to Pfizer, with whom BioNTech had previously started work on a flu vaccine, and researchers at the two companies began working together even before commercial contracts had been signed.

“This trust-based relationship is one of the key factors why we have been so fast, because it allowed us to share data, to share information, to start to avoid any type of delay,” Sahin said.

What followed was a flurry of activity as BioNTech and Pfizer raced rivals such as Johnson & Johnson, AstraZeneca and Moderna to become the first to get emergency authorisation for a COVID vaccine. Unlike rivals in China and Russia, all of the companies have followed the established path of conducting trials in three stages, publishing results as they go along and submitting them to independent regulators for review.

While authorities in the United States, the United Kingdom and the European Union indicated they would make a decision before the end of the year, it wasn’t clear who would be first until UK authorities announced they’d approved the BioNTech-Pfizer shot on Wednesday.

“It was (an email) very early this morning, in the early, early hours from the regulators saying we had received approval,” BioNTech’s Chief Commercial Officer, Sean Marett, told The AP.

Marett, a softly spoken Brit with long experience in the pharmaceutical industry, said the company hasn’t had time to celebrate yet.

“We’re too busy worrying about packing boxes for the UK,” he said, adding that the first shipments would likely hit the road in the coming 24 to 48 hours.

Marett dismissed suggestions that British authorities might have taken shortcuts, saying they had asked “very, very deep questions, and detailed questions, just like any other agency”.

BioNTech hopes sales of the vaccine will more than cover the cost of development and production. Together with Pfizer and Chinese distributor Fosun Pharma, it hopes to ship at least 1.3 billion doses of the COVID vaccine in 2021.

“We’re a biotechnology company, loss-making, and of course, we need to generate some money so we can keep in business,” he said.

Marett said the company currently has 1,800 staff and expects to grow in the coming years; its focus will remain on pushing developing new drugs. Sahin, who co-founded BioNTech along with Ozlem Tureci, his wife, said that aside from the flu vaccine being developed with Pfizer, the company is also already working with others on a dozen different shots, including for HIV and tuberculosis.

“BioNTech stands for Bio New Technologies, and that’s what fascinates us about what we can do, really use new technologies to address disease,” Marett told The AP. “We’ve hopefully demonstrated, at least with the first approval, that that approach may be useful to society.”